Microcapsule-Based Estrogen Delivery System for Hormone Replacement
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hormone replacement therapy methods using pharmacological delivery of estrogens result in consistently high serum concentrations, leading to clinical complications such as increased incidence of heart disease and cancer, necessitating new methods for estrogen delivery.
Innovation Solution
A composition of microcapsules containing live mammalian ovarian granulosa cells and theca cells, optionally with semipermeable layers, for controlled delivery of estrogen and progesterone, minimizing oocyte presence and immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pharmacological delivery of estrogens is used, then hormone replacement therapy is achieved, but consistently high serum concentrations occur leading to increased incidence of heart disease and cancer
Solution Approach 1:
The invention segments the estrogen delivery system by using individual microcapsules containing encapsulated ovarian cells, each capsule acting as an independent unit that releases hormones locally rather than systemically. This segmentation allows controlled, localized hormone delivery that reduces peak serum concentrations while maintaining therapeutic effects.
Solution Approach 2:
The invention changes the delivery parameters from pharmacological (systemic, high concentration) to biological (cell-based, controlled release). The encapsulated cells provide sustained hormone production over time, transforming the concentration-time profile from sharp peaks to prolonged low-level release, thereby reducing harmful side effects.
2Duration of action of moving object
If live mammalian ovarian granulosa cells and theca cells are encapsulated together, then sustained estrogen and progesterone production is achieved, but complex microcapsule structure is required
Solution Approach 1:
The invention merges granulosa cells and theca cells into a single microcapsule structure, allowing both cell types to coexist and function together. This combination enables simultaneous production of estrogen by granulosa cells and progesterone by theca cells within one integrated system, achieving sustained dual-hormone delivery without requiring separate capsule structures.
Solution Approach 2:
The microcapsule structure serves multiple functions simultaneously: it encapsulates and protects both cell types, provides selective permeability for hormone release, maintains cellular viability, and enables sustained production of multiple hormones. This multi-functionality reduces the need for separate structural components.
3Manufacturing precision
If semipermeable layers are added to microcapsules, then controlled delivery of hormones is improved, but manufacturing complexity increases
Solution Approach 1:
The invention uses semipermeable porous materials for the microcapsule layers, which allow controlled diffusion of hormones based on molecular size and concentration gradients. The porous structure provides inherent control mechanisms that simplify manufacturing compared to active pumping systems, as the controlled delivery is achieved passively through the material's physical properties.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The microcapsule-based delivery system provides sustained production of estrogens and progesterones, reducing systemic side effects and achieving therapeutic benefits while maintaining cellular viability and steroidogenic potency.
Implementation Method 1
The microcapsules further comprising a first semipermeable layer between the core and the auxiliary layer. In some embodiments, the microcapsules further comprising a second semipermeable layer surrounding the auxiliary layer.
Implementation Method 2
the microcapsules comprise a hydrogel such as a polysaccharide hydrogel (e.g., wherein the core comprises a hydrogel such as a polysaccharide hydrogel, and the surrounding layer comprises a hydrogel such as a polysaccharide hydrogel)
Implementation Method 3
the microcapsules comprise a hydrogel such as a polysaccharide hydrogel
Data Source
AI summary
A composition comprising microcapsules, the microcapsules containing both live mammalian ovarian granulosa cells and live mammalian ovarian theca cells, is described. In some embodiments, the granulosa cells and the theca cells are contained in separate microcapsules in the composition; in some embodiments, the granulosa cells and the theca cells are contained together in the same microcapsules in the composition The composition is can be used for estrogen, and optionally also progesterone, delivery, and hence is preferably free or essentially free of oocytes. Methods of using the same and pharmaceutical formulations containing the same are also described.